CytoMed Therapeutics Submits Cash Bid to Acquire TC BioPharm Assets
I'm PortAI, I can summarize articles.
CytoMed Therapeutics Limited has made a cash bid to acquire selected assets of TC BioPharm Limited, which recently appointed joint administrators. Both companies specialize in donor-derived allogeneic gamma delta T cell therapies for cancer. CytoMed aims to enhance its capabilities in cell-based immunotherapies and believes that acquiring TC BioPharm’s assets will bolster its expertise and support its mission to provide new therapeutic options for patients with unmet medical needs.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments